<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116541</url>
  </required_header>
  <id_info>
    <org_study_id>ET19-073 (MegaMOST)</org_study_id>
    <secondary_id>2019-001494-88</secondary_id>
    <nct_id>NCT04116541</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.</brief_title>
  <acronym>MegaMOST</acronym>
  <official_title>MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicenter, open-label, biology driven, phase II study using a sequential&#xD;
      Bayesian design, aiming to assess the efficacy and safety of different Matched Targeted&#xD;
      Therapy (MTT) in independent and parallel cohorts of treatment.&#xD;
&#xD;
      Patients will be assigned to a treatment cohort based on molecular&#xD;
      alterations/characteristics detected on tumor sample from primary tumor or metastatic lesion.&#xD;
&#xD;
      In this protocol, several MTTs treatment cohorts are planned. This study is designed with the&#xD;
      flexibility to open new MTTs treatment cohorts and to close existing MTTs treatment cohorts&#xD;
      that demonstrate no clinical benefit. Each treatment cohort will be driven separately even&#xD;
      though procedures, quality control and reporting, will be common. The protocol will be&#xD;
      amended in order to include new treatments or combinations that emerge as being of interest&#xD;
      for patients with advanced/metastatic cancers.&#xD;
&#xD;
      All eligible patients will receive study drugs as long as patient experiences clinical&#xD;
      benefit in the opinion of the investigator, or until unacceptable toxicity, or until&#xD;
      symptomatic deterioration attributed to disease progression as determined by the investigator&#xD;
      after an integrated assessment of radiographic data and clinical status, or withdrawal of&#xD;
      consent.&#xD;
&#xD;
      Patients will be permitted to continue study treatment after progressive disease according to&#xD;
      RECIST v1.1 if they meet all of the following criteria and following validation of the&#xD;
      Sponsor:&#xD;
&#xD;
        -  Evidence of clinical benefit as assessed by the investigators,&#xD;
&#xD;
        -  Absence of symptoms and signs (including worsening of laboratory values; e.g., new or&#xD;
           worsening hypercalcemia) that indicate unequivocal progression of disease,&#xD;
&#xD;
        -  No decline in ECOG Performance Status (PS) that can be attributed to disease&#xD;
           progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free rate after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>The proportion of patients with a complete response (CR), a partial response (PR) or a stable disease (SD) at 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate after 3 months of treatment</measure>
    <time_frame>3 months</time_frame>
    <description>The proportion of patients with a complete or a partial response (CR or PR) as best overall response at 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Duration of response applies only to patients whose best overall response was a complete response or a partial response (CR or PR). It will be defined as the time from the date of first documented response (CR or PR) to the date of the first documented progression or death due to underlying cancer and censored at the date of the last adequate tumor assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The time from the date of the first study drug administration to the first documented progression according to investigator assessment of RECIST version 1.1 or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The time from the date of the first study drug administration to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of long-term responders (&gt; 6 months)</measure>
    <time_frame>6 months</time_frame>
    <description>The proportion of long term responders (&gt; 6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Nature, frequency and severity of Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) graded using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HDM201 + Ribociclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with documented amplification of Cyclin-dependent kinase 6 (CDK6) and/or Cyclin-dependent kinase 4 (CDK4), and/or cyclin dependent kinase inhibitor 2A (CDKN2A) homozygous deletion, and/or amplification of Cyclin D1 (CCND1) and/or Cyclin D3 (CCND3) with no deletion/losses more than single copy of retinoblastoma 1 (RB1) by copy number and P53 wild-type detected on tumor sample from primary tumor or metastatic lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with AXL, MET, vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), KIT, RET, ROS1, MER, Tropomyosin receptor kinase B (TRKB), Fms-like tyrosine kinase 3 (FLT3), TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK translocation detected on tumor sample from primary tumor or metastatic lesion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alectinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with ALK alterations: translocation, mutation or amplification</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <description>HDM201 120mg, Every 3 weeks, Per os</description>
    <arm_group_label>HDM201 + Ribociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os</description>
    <arm_group_label>HDM201 + Ribociclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib, 60 mg /day, continuous, Per os</description>
    <arm_group_label>Cabozantinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alectinib</intervention_name>
    <description>Alectinib, 600mg twice daily, Per os</description>
    <arm_group_label>Alectinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged of at least 18 years on day of signing informed consent.&#xD;
&#xD;
          -  Patients with histologically confirmed diagnosis of metastatic disease or unresectable&#xD;
             locally advanced malignancy that is resistant or refractory to standard therapies or&#xD;
             for which standard therapies does not exist or is/are not considered appropriate by&#xD;
             the investigator.&#xD;
&#xD;
          -  A multidisciplinary molecular board must have recommended the specific MTT based on&#xD;
             the following documented actionable alterations:&#xD;
&#xD;
               -  Cohort HDM201-Ribociclib : amplification of CDK6 and/or CDK4, and/or CDKN2A&#xD;
                  homozygous deletion, and/or amplification of CCND1 and/or CCND3 with no&#xD;
                  deletion/losses more than single copy of RB1 by copy number and P53 wild-type.&#xD;
&#xD;
               -  Cohort Cabozantinib : AXL, MET, VEGFR, VEGF, KIT, RET, ROS1, MER, TRKB, FLT3,&#xD;
                  TIE-2 and/or Tyro3 activating mutations and/or amplification, and/or NTRK&#xD;
                  translocation&#xD;
&#xD;
               -  Cohort Alectinib : Activating ALK alterations: translocation, mutation or&#xD;
                  amplification&#xD;
&#xD;
          -  Previously treated by at least one prior line of treatment in the advanced/metastatic&#xD;
             setting.&#xD;
&#xD;
          -  Documented radiological disease progression as per RECIST v1.1 and presence of at&#xD;
             least one measurable lesion according to RECIST 1.1 criteria based on screening tumor&#xD;
             assessment.&#xD;
&#xD;
          -  Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group&#xD;
             (ECOG) scale.&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequate cardiovascular function&#xD;
&#xD;
          -  Specific toxicities related to any prior anti-cancer therapy must have resolved to&#xD;
             grade ≤1 , except for alopecia (all grades), grade 2 neuropathy or anemia.&#xD;
&#xD;
          -  Unless infertility is proven, men must agree to use effective contraception&#xD;
&#xD;
          -  Women of child-bearing potential must have a negative serum pregnancy test within 7&#xD;
             days of first dose of study drug and agree to use effective contraception&#xD;
&#xD;
          -  Patient should understand, sign, and date the written voluntary informed consent form&#xD;
             prior to any protocol-specific procedures performed. Patient should be able and&#xD;
             willing to comply with study procedures as per protocol.&#xD;
&#xD;
          -  Patient must be covered by a medical insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients amenable to therapy with curative intent.&#xD;
&#xD;
          -  Patients participating to another clinical trial with a medicinal product.&#xD;
&#xD;
          -  Patients previously treated with similar MTT meaning any agent targeting the same&#xD;
             signaling pathways components.&#xD;
&#xD;
          -  Patients unable to swallow oral medication.&#xD;
&#xD;
          -  Patients with known hypersensitivity to excipients&#xD;
&#xD;
          -  Patients with symptomatic central nervous system (CNS) metastasis who are&#xD;
             neurologically unstable or require increasing doses of corticosteroids or local&#xD;
             CNS-directed therapy to control their CNS disease.&#xD;
&#xD;
          -  Patients with secondary malignancy unless this malignancy is not expected to interfere&#xD;
             with the evaluation of study endpoints and is approved by the sponsor. Examples of the&#xD;
             latter include: basal or squamous cell carcinoma of the skin, in-situ carcinoma of the&#xD;
             cervix, localized prostate cancer, prior malignancy and no evidence of recurrence for&#xD;
             ≥ 2 years.&#xD;
&#xD;
          -  Patients using, or requirement to use while on the study, or not respecting the&#xD;
             minimal wash-out period of medications (4 weeks for anti-cancer systemic treatment,&#xD;
             Chemotherapy, Radiotherapy, Surgery, Live vaccines ; 2 weeks for Growth Factors&#xD;
             targeting the myeloid lineage; 1 week for medication known to prolong the QT interval,&#xD;
             Strong inducers or inhibitors of CYP3A4/5, Oral anticoagulants)&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B (HBV) or&#xD;
             Hepatitis C (HCV) infection.&#xD;
&#xD;
          -  Any clinically significant and/or uncontrolled medical disease that could compromise&#xD;
             the patient's ability to tolerate study drug or would likely interfere with study&#xD;
             procedures or results.&#xD;
&#xD;
          -  Patients with known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding women or expecting to conceive or father&#xD;
             children within the projected duration of the trial, starting with the screening visit&#xD;
             through 21 days after the last dose of trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Yves BLAY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Yves BLAY, MD</last_name>
    <phone>+33478785126</phone>
    <email>jean-yves.blay@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier TREDAN, MD</last_name>
    <phone>+33478782828</phone>
    <email>olivier.tredan@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO, PHD</last_name>
      <phone>05 56 33 32 44</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Kevin BOURCIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie COUSIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas GRELLETY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon PERNOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille MAZZA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego TEYSSONNEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maud TOULMONDE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves BLAY, MD</last_name>
      <phone>04 78 78 27 57</phone>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier TREDAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BERTUCCI, MD</last_name>
      <phone>04 91 22 35 37</phone>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anthony GONCALVES, MD</last_name>
      <phone>04 91 22 37 89</phone>
      <email>goncalvesa@ipc.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>François BERTUCCI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony GONCALVES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma SAADA-BOUZID, MD</last_name>
      <phone>04 92 03 15 14</phone>
      <email>esma.saada-bouzid@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Esma SAADA-BOUZID, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agnès DUCOULOMBIER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joël GUIGAY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MARTIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magalie Pascale TARDY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <phone>01 44 32 46 75</phone>
      <email>christophe.letourneau@curie.fr</email>
    </contact>
    <contact_backup>
      <last_name>Delphine LOIRAT, MD</last_name>
      <phone>01 44 32 46 75</phone>
      <email>delphine.loirat@curie.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Christophe LE TOURNEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine LOIRAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Paule SABLIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos-Alberto GOMEZ-ROCA, MD</last_name>
      <phone>05 31 15 51 01</phone>
      <email>gomez-roca.carlos@iuct-oncopole.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Pierre DELORD, MD</last_name>
      <phone>05 31 15 51 01</phone>
      <email>delord.jean-pierre@iuct-oncopole.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos-Alberto GOMEZ-ROCA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Pierre DELORD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iphigénie KORAKIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Solid Neoplasm</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Genomic alteration</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Cabozantinib</keyword>
  <keyword>Ribociclib</keyword>
  <keyword>HDM201</keyword>
  <keyword>Alectinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

